Middle East and Africa HPV Vaccines Market

ID: MRFR/Pharma/14658-HCR
128 Pages
Vikita Thakur
Last Updated: April 06, 2026
Middle East and Africa HPV Vaccines Market Research Report Information By Vaccine Type (Quadrivalent HPV Vaccines, Bivalent HPV Vaccines, and Nonavalent HPV Vaccines), By Target Population (Girls & Women, and Boys & Men), By End-User (Hospitals, Clinics, Doctors’ Offices, and Schools) –and Middle East and Africa Market Forecast Till 2035
Middle East and Africa HPV Vaccines Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)2.16%
2024 Market Size$ 143.85 Million
2025 Market Size$ 147.3 Million
2035 Market Size$ 182 Million
Key Players
Merck & Co.
GlaxoSmithKline
Sanofi
Pfizer
Bharat Biotech
Serum Institute of India
Trends
  • Increased Public Awareness
  • Technological Advancements in Vaccines
  • Collaborative Health Initiatives
Opportunities
  • Increased Government Initiatives
  • Enhanced Healthcare Infrastructure
  • Rising Incidence of HPV-Related Cancers
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Prevention
      2. 4.1.2 Therapeutic
      3. 4.1.3 Screening
      4. 4.1.4 Research
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Clinics
      3. 4.2.3 Research Institutions
      4. 4.2.4 Pharmacies
    3. 4.3 Healthcare, BY Age Group (USD Million)
      1. 4.3.1 Adolescents
      2. 4.3.2 Young Adults
      3. 4.3.3 Adults
      4. 4.3.4 Elderly
    4. 4.4 Healthcare, BY Gender (USD Million)
      1. 4.4.1 Female
      2. 4.4.2 Male
      3. 4.4.3 Non-binary
    5. 4.5 Healthcare, BY Administration Route (USD Million)
      1. 4.5.1 Intramuscular
      2. 4.5.2 Subcutaneous
      3. 4.5.3 Oral
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Merck & Co. (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 GlaxoSmithKline (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sanofi (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bharat Biotech (IN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Serum Institute of India (IN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Cipla (IN)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Mylan (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 MEA MARKET ANALYSIS BY APPLICATION
    3. 6.3 MEA MARKET ANALYSIS BY END USE
    4. 6.4 MEA MARKET ANALYSIS BY AGE GROUP
    5. 6.5 MEA MARKET ANALYSIS BY GENDER
    6. 6.6 MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY GENDER, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY GENDER, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY AGE GROUP, 2026-2035 (USD Million)
      4. 7.2.4 BY GENDER, 2026-2035 (USD Million)
      5. 7.2.5 BY ADMINISTRATION ROUTE, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

MEA Middle East and Africa HPV Vaccines Market Segmentation

Middle East and Africa HPV Vaccines Market By Application (USD Million, 2026-2035)

  • Prevention
  • Therapeutic
  • Screening
  • Research

Middle East and Africa HPV Vaccines Market By End Use (USD Million, 2026-2035)

  • Hospitals
  • Clinics
  • Research Institutions
  • Pharmacies

Middle East and Africa HPV Vaccines Market By Age Group (USD Million, 2026-2035)

  • Adolescents
  • Young Adults
  • Adults
  • Elderly

Middle East and Africa HPV Vaccines Market By Gender (USD Million, 2026-2035)

  • Female
  • Male
  • Non-binary

Middle East and Africa HPV Vaccines Market By Administration Route (USD Million, 2026-2035)

  • Intramuscular
  • Subcutaneous
  • Oral

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.